Sang-jin Daniel Lee
Equibles does not estimate personal net worth.
Get an email with a short summary when Liminatus Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get LIMN alertsAbout Sang-jin Daniel Lee
Liminatus Pharma, Inc. reported in an 8-K filed May 6, 2025 that Sang-jin Daniel Lee was appointed Head of Research and Development. Liminatus Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Liminatus Pharma, Inc. includes Chris Kim (CEO and Board Member), Scott Dam (CFO), Beom K. Choi (CTO) and 5 others.
“Further, upon the consummation of the Business Combination, (i) Sumit Mehta resigned from his position as Chief Executive Officer, Lisha Parmar resigned from her position as Chief Financial Officer and Omkar Halady resigned from his position as Vice President, and (ii) Chris Kim was appointed as Chief Executive Officer, Scott Dam was appointed as Chief Financial Officer, Byong C. Yoo was appointed as Chief Science Officer, Sang-jin Daniel Lee was appointed as Head of Research and Development, and Beom K. Choi was appointed as Chief Technology Officer.”
Affiliation history
-
Liminatus Pharma, Inc. (LIMN)
Proxy statement
CurrentStart not stated–present
Last confirmed July 13, 2026
Company network
Leadership on record at Liminatus Pharma, Inc.
- Chris Kim CEO, Board Member
- Scott Dam CFO
- Beom K. Choi CTO
- Eun Sook Lee Board Member
- Ji Yeon Baek Board Member
- Nicholas Fernandez Board Member
- Philip Lemons Board Member
- Richard Baek Board Member